Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Post-procedural three-dimensional (3D) quantitative coronary angiography (QCA)-based vessel fractional flow reserve (vFFR) has shown a strong correlation with invasive FFR measurements. However, the relationship between post-percutaneous coronary intervention (PCI) vFFR, vFFR-derived pressure pullback gradient (PPG), clinical outcomes, and post-PCI quality of life (QoL) concerning sex differences remains unexplored.
Methods: This single-centre retrospective study included patients undergoing PCI for stable or unstable angina, or non-ST-elevation myocardial infarction (NSTEMI) with two angiographic views suitable for post-PCI vFFR calculation and complete QoL assessment. Post-PCI QoL was assessed using EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire and Seattle Angina Questionnaire (SAQ). Focal disease was defined as vFFR-derived PPG ≥0.74, diffuse as values <0.74. QoL and clinical outcomes were analyzed and compared between sexes.
Results: A total of 234 patients (286 vessels) were analyzed, with median follow-up of 4.21 years. The median post-PCI vFFR was 0.92 (IQR 0.90-0.95), and the median vFFR-derived PPG was 0.74 (IQR 0.65-0.84), with no significant differences between sexes. Among patients with high post-PCI vFFR (above the median of 0.92), females had lower EQ index score than males (p < 0.001). In the middle post-PCI vFFR tertile (vFFR between 0.88 and 0.93), females had lower SAQ Summary scores than males (p < 0.001). Females had significantly lower EQ Index and SAQ Summary scores compared to males among patients with both focal and diffuse disease, with all p-values <0.05. There were no differences in clinical outcomes between sexes.
Conclusion: This finding suggests that vFFR may be associated with post-procedural QoL, which in our study was lower in women than in men-though inconsistently across instruments or domains-despite similar post-PCI vFFR and vFFR-derived PPG values, warranting confirmation in larger, prospective studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2025.133771 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Presbyopia-correcting intraocular lenses in eyes with corneal conditions: an update.
Curr Opin Ophthalmol
September 2025
Singapore Eye Research Institute, Singapore National Eye Centre.
Purpose Of Review: Modern presbyopia-correcting intraocular lenses (IOLs) offer a potential solution to address the rising postoperative demand and expectations for spectacle independence following cataract surgery. However, IOL calculation and selection becomes more complex when presented with previous corneal refractive surgery (CRS) or co-existing corneal conditions. This review explores the use of presbyopia-correcting IOLs in eyes with co-existing corneal conditions or surgically altered corneas.
View Article and Find Full Text PDFThe CONDUCT-AF trial: Rationale and design of a prospective, randomized, multicentre study comparing conduction system and biventricular pacing in patients undergoing atrioventricular node ablation for heart failure with atrial fibrillation.
Eur J Heart Fail
September 2025
Cardiology Department, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Aims: There is a lack of data from randomized clinical trials comparing treatment outcomes between conduction system pacing (CSP) modalities and biventricular pacing (BVP) in symptomatic patients with refractory atrial fibrillation (AF) scheduled for atrioventricular node ablation (AVNA). The CONDUCT-AF investigates whether CSP is non-inferior to BVP in improving left ventricular ejection fraction (LVEF) and clinical outcomes in heart failure (HF) patients with symptomatic AF undergoing AVNA.
Methods: This study is an investigator-initiated, prospective, randomized, multicentre clinical trial conducted across 10 European centres, enrolling 82 patients with symptomatic AF, HF with reduced LVEF, and narrow QRS.
Metastatic Breast Cancer mHealth App to Promote Patient-Provider Communication: Protocol for a Usability and Satisfaction Study.
JMIR Res Protoc
September 2025
Department of Health Services Research & Administration, College of Public Health, University of Nebraska Medical Center, Omaha, NE, United States.
Background: With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC.
View Article and Find Full Text PDFFermented Food Consumption Across European Regions: Protocol for the Development and Validation of the Web-Based Fermented Foods Frequency Questionnaire (3FQ).
JMIR Res Protoc
September 2025
Department of Food Science and Technology, Kaunas University of Technology, Kaunas, Lithuania.
Background: Fermented foods vary significantly by food substrate and regional consumption patterns. Although they are consumed worldwide, their intake and potential health benefits remain understudied. Europe, in particular, lacks specific consumption recommendations for most fermented foods.
View Article and Find Full Text PDFElinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
JAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).